AETHLON MEDICAL Aktie

>AETHLON MEDICAL Performance

1 Woche: 0%

1 Monat: 0%

3 Monate: 0%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: 0%

>AETHLON MEDICAL Aktie

Name:

AETHLON MEDICAL

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US00808Y6041 / A41NJ5

Symbol/ Ticker:

EJU1 (Frankfurt) / AEMD (NASDAQ)

Kürzel:

FRA:EJU1, ETR:EJU1, EJU1:GR, NASDAQ:AEMD

Index:

Webseite:

https://www.aethlonmedica..

Profil:

Marktkapitalisierung:

2.42 Mio. EUR

Unternehmenswert:

-3.25 Mio. EUR

Umsatz:

EBITDA:

-5.91 Mio. EUR

Nettogewinn:

-9.98 Mio. EUR

Gewinn je Aktie:

-39.71 EUR

Schulden:

0.36 Mio. EUR

Liquide Mittel:

6.03 Mio. EUR

Operativer Cashflow:

-6 Mio. EUR

Bargeldquote:

5.53

Umsatzwachstum:

Gewinnwachstum:

-20.54%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

AETHLON MEDICAL

Letzte Datenerhebung:

05.04.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 1.32 Mio. St.

Frei handelbar: 92.86%

Leerverk. Aktien: -

Rückkaufquote: -368.6%

Mitarbeiter: 9

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Neutral

Kursziel: 442.45%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 0.31

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -158.03%

Eigenkaprendite: -208.6%

>Peer Group

Gesundheit

>AETHLON MEDICAL Chart & Kurs - NASDAQ

>AETHLON MEDICAL News

24.03.26 - 13:03	Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review (PR Newswire)
	SAN DIEGO, March 24, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced that the independent Data Safety......

12.03.26 - 19:18	Aethlon Medical stellt Onkologie-Fokus des Hemopurifier auf Investorenforum vor (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

12.03.26 - 13:03	Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities (PR Newswire)
	SAN DIEGO, March 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is evaluating a range of strategic......

25.02.26 - 23:18	Aethlon Medical stellt auf Konferenz Onkologie-Strategie für Hemopurifier vor (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

23.02.26 - 14:03	Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026 (PR Newswire)
	Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference. SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical......

13.02.26 - 04:21	Aethlon Medical signals faster clinical trial enrollment amid Hemopurifier advancements (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 23:36	Earnings Call Q3 2026: Operative Fortschritte bei Aethlon Medical von finanziellen Herausforderungen überschattet (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 22:36	Aethlon Medical GAAP EPS of -$2.45 misses by $0.03 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 22:18	Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update (PR Newswire)
	Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing......

04.02.26 - 14:03	Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026 (PR Newswire)
	SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended......

05.12.25 - 16:01	Aethlon Medical: Aktie fällt nach Ankündigung einer Privatplatzierung über 3,3 Mio. US-Dollar (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

05.12.25 - 15:18	Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million (PR Newswire)
	SAN DIEGO, Dec. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it has entered into a securities purchase......

02.12.25 - 17:48	Aethlon Medical-Aktie im Aufwind: Studie stützt Potenzial des Hemopurifiers bei Long-COVID (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

02.12.25 - 14:03	Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs (PR Newswire)
	Results Support the Further Investigation of the Hemopurifier in Long COVID SAN DIEGO, Dec. 2, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, announced today......

13.11.25 - 00:36	Aethlon Medical signals expanded Australian oncology enrollment strategy while operating loss narrows to $1.5M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.11.25 - 22:18	Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update (PR Newswire)
	Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m. ET SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to......

07.11.25 - 14:03	Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025 (PR Newswire)
	SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended......

20.10.25 - 08:12	XFRA: EJU1: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL AETHL.MED. OCT.25 DL-,001 EJU1 US00808Y6041 BAW/UFN...

20.10.25 - 07:57	XFRA: INSTRUMENT_SUSPENSION - US00808Y6041 (XETRA)
	Instrument ID [25876513] (EJU1 - US00808Y6041) suspended...

19.10.25 - 21:33	XFRA: NEW INSTRUMENT AVAILABLE - 20.10.2025 - US00808Y6041 (XETRA)
	Das Instrument EJU1 US00808Y6041 AETHL.MED. OCT.25 DL-,001 EQUITY hat seinen ersten Handelstag am 20.10.2025: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N The instrument EJU1 US00808Y6041 AETHL.MED. OCT.25 DL-,001 EQUITY has its first trading date on 20.10.2025: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram